| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 60 | 2026 | 3158 | 5.050 |
Why?
|
| Magnetic Resonance Imaging | 45 | 2026 | 3479 | 4.060 |
Why?
|
| Contrast Media | 36 | 2026 | 989 | 2.250 |
Why?
|
| Stomach Neoplasms | 9 | 2024 | 308 | 2.150 |
Why?
|
| Lymph Nodes | 8 | 2021 | 548 | 2.050 |
Why?
|
| Axilla | 11 | 2021 | 109 | 1.880 |
Why?
|
| Lymphatic Metastasis | 11 | 2017 | 505 | 1.830 |
Why?
|
| Ultrasonography, Mammary | 7 | 2013 | 84 | 1.580 |
Why?
|
| Receptor, ErbB-2 | 6 | 2024 | 280 | 1.570 |
Why?
|
| Carcinoma, Ductal, Breast | 6 | 2021 | 166 | 1.410 |
Why?
|
| Image Interpretation, Computer-Assisted | 14 | 2018 | 629 | 1.350 |
Why?
|
| Image Enhancement | 13 | 2021 | 505 | 1.260 |
Why?
|
| Breast | 13 | 2022 | 303 | 1.220 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 13 | 2020 | 461 | 1.140 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 5 | 2021 | 122 | 1.110 |
Why?
|
| Gadolinium DTPA | 13 | 2015 | 233 | 1.090 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2023 | 59 | 1.020 |
Why?
|
| Sensitivity and Specificity | 26 | 2023 | 1924 | 0.930 |
Why?
|
| B7-H1 Antigen | 2 | 2024 | 305 | 0.880 |
Why?
|
| Carcinoma | 2 | 2021 | 439 | 0.850 |
Why?
|
| ROC Curve | 19 | 2015 | 775 | 0.830 |
Why?
|
| Biopsy | 14 | 2022 | 1177 | 0.800 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 5 | 2022 | 299 | 0.780 |
Why?
|
| Mammography | 9 | 2021 | 494 | 0.770 |
Why?
|
| Humans | 104 | 2026 | 93613 | 0.740 |
Why?
|
| Stomach | 2 | 2022 | 113 | 0.740 |
Why?
|
| Artificial Intelligence | 3 | 2023 | 395 | 0.740 |
Why?
|
| Middle Aged | 54 | 2026 | 27623 | 0.730 |
Why?
|
| Aged | 44 | 2026 | 20472 | 0.720 |
Why?
|
| Female | 71 | 2026 | 48781 | 0.710 |
Why?
|
| Neoadjuvant Therapy | 8 | 2026 | 446 | 0.700 |
Why?
|
| Radiologists | 1 | 2021 | 57 | 0.650 |
Why?
|
| Adult | 44 | 2026 | 27949 | 0.650 |
Why?
|
| Carcinogenesis | 2 | 2023 | 235 | 0.640 |
Why?
|
| Diagnosis, Differential | 20 | 2022 | 1546 | 0.640 |
Why?
|
| Radiography, Thoracic | 9 | 2006 | 327 | 0.630 |
Why?
|
| Diagnosis, Computer-Assisted | 7 | 2011 | 337 | 0.600 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2024 | 624 | 0.590 |
Why?
|
| Biopsy, Needle | 3 | 2010 | 226 | 0.540 |
Why?
|
| Mass Screening | 6 | 2018 | 708 | 0.530 |
Why?
|
| Kinetics | 9 | 2023 | 1470 | 0.530 |
Why?
|
| Retrospective Studies | 27 | 2026 | 10185 | 0.530 |
Why?
|
| Aged, 80 and over | 22 | 2025 | 7072 | 0.510 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 1661 | 0.500 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 774 | 0.460 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 1233 | 0.460 |
Why?
|
| Observer Variation | 14 | 2020 | 571 | 0.420 |
Why?
|
| User-Computer Interface | 3 | 2012 | 189 | 0.400 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 1054 | 0.400 |
Why?
|
| Transcription Factors | 1 | 2021 | 1690 | 0.390 |
Why?
|
| Ultrasonography, Interventional | 2 | 2013 | 121 | 0.370 |
Why?
|
| Diagnostic Imaging | 2 | 2013 | 456 | 0.360 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2026 | 1262 | 0.350 |
Why?
|
| Lung Diseases, Interstitial | 4 | 2005 | 292 | 0.340 |
Why?
|
| Lung Neoplasms | 11 | 2008 | 2368 | 0.320 |
Why?
|
| Organometallic Compounds | 3 | 2016 | 139 | 0.320 |
Why?
|
| Prognosis | 6 | 2026 | 3915 | 0.310 |
Why?
|
| Secretoglobins | 3 | 2024 | 4 | 0.310 |
Why?
|
| Neoplasm Staging | 8 | 2018 | 2017 | 0.310 |
Why?
|
| Tomography, Spiral Computed | 3 | 2004 | 76 | 0.310 |
Why?
|
| Prospective Studies | 12 | 2025 | 4563 | 0.290 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2023 | 306 | 0.290 |
Why?
|
| Reproducibility of Results | 14 | 2022 | 2718 | 0.290 |
Why?
|
| Decision Making | 1 | 2013 | 674 | 0.280 |
Why?
|
| Lung Diseases | 4 | 2004 | 283 | 0.270 |
Why?
|
| Solitary Pulmonary Nodule | 7 | 2006 | 139 | 0.270 |
Why?
|
| Japan | 3 | 2024 | 299 | 0.260 |
Why?
|
| Herpesvirus 4, Human | 3 | 2023 | 122 | 0.260 |
Why?
|
| Mastectomy, Segmental | 2 | 2021 | 108 | 0.250 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2025 | 2593 | 0.240 |
Why?
|
| Ultrasonography | 3 | 2017 | 702 | 0.240 |
Why?
|
| Amyloid | 2 | 2023 | 104 | 0.230 |
Why?
|
| Pancreatic Juice | 1 | 2025 | 2 | 0.230 |
Why?
|
| Blood Sedimentation | 1 | 2025 | 13 | 0.230 |
Why?
|
| Young Adult | 8 | 2021 | 6937 | 0.230 |
Why?
|
| Meglumine | 2 | 2016 | 36 | 0.220 |
Why?
|
| Pattern Recognition, Automated | 4 | 2011 | 217 | 0.220 |
Why?
|
| Postoperative Hemorrhage | 1 | 2025 | 49 | 0.220 |
Why?
|
| Calcinosis | 4 | 2011 | 222 | 0.220 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2025 | 92 | 0.220 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2021 | 512 | 0.210 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2017 | 86 | 0.200 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2016 | 608 | 0.200 |
Why?
|
| Immunohistochemistry | 2 | 2024 | 1790 | 0.200 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2023 | 16 | 0.200 |
Why?
|
| Prealbumin | 1 | 2023 | 45 | 0.200 |
Why?
|
| Mass Spectrometry | 1 | 2023 | 198 | 0.190 |
Why?
|
| Breast Density | 2 | 2020 | 42 | 0.190 |
Why?
|
| Pulmonary Emphysema | 1 | 2023 | 43 | 0.190 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2022 | 29 | 0.180 |
Why?
|
| Hospital Mortality | 1 | 2025 | 483 | 0.180 |
Why?
|
| Thrombosis | 1 | 2025 | 309 | 0.180 |
Why?
|
| Nucleic Acids | 1 | 2022 | 35 | 0.180 |
Why?
|
| Preoperative Care | 2 | 2016 | 407 | 0.180 |
Why?
|
| Cigarette Smoking | 1 | 2023 | 47 | 0.180 |
Why?
|
| Peptide Fragments | 2 | 2022 | 469 | 0.180 |
Why?
|
| Communicable Diseases | 1 | 2023 | 69 | 0.180 |
Why?
|
| Emphysema | 1 | 2022 | 24 | 0.180 |
Why?
|
| Lung | 8 | 2024 | 1365 | 0.180 |
Why?
|
| Gene Knockout Techniques | 1 | 2021 | 83 | 0.170 |
Why?
|
| Incidental Findings | 2 | 2013 | 97 | 0.170 |
Why?
|
| Gastric Mucosa | 1 | 2021 | 71 | 0.170 |
Why?
|
| Algorithms | 8 | 2017 | 1956 | 0.170 |
Why?
|
| Transcriptome | 2 | 2023 | 761 | 0.170 |
Why?
|
| Periodontal Diseases | 1 | 2020 | 10 | 0.170 |
Why?
|
| Pulmonary Fibrosis | 1 | 2023 | 152 | 0.170 |
Why?
|
| Amyloidosis | 1 | 2022 | 132 | 0.160 |
Why?
|
| Nanotubes | 1 | 2020 | 10 | 0.160 |
Why?
|
| Silicon | 1 | 2020 | 20 | 0.160 |
Why?
|
| Apoptosis | 2 | 2024 | 1719 | 0.160 |
Why?
|
| Hepatitis B, Chronic | 1 | 2020 | 34 | 0.160 |
Why?
|
| Lymphoma | 1 | 2022 | 246 | 0.160 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2020 | 40 | 0.160 |
Why?
|
| Reference Standards | 1 | 2021 | 146 | 0.160 |
Why?
|
| Hepatitis B | 1 | 2020 | 77 | 0.160 |
Why?
|
| Methane | 1 | 2020 | 14 | 0.160 |
Why?
|
| Animal Feed | 1 | 2020 | 22 | 0.160 |
Why?
|
| DNA Methylation | 2 | 2021 | 697 | 0.160 |
Why?
|
| Radiographic Image Enhancement | 4 | 2009 | 449 | 0.150 |
Why?
|
| Transforming Growth Factor beta | 1 | 2022 | 347 | 0.150 |
Why?
|
| Dietary Fiber | 1 | 2020 | 46 | 0.150 |
Why?
|
| Fibroadenoma | 1 | 2019 | 7 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 240 | 0.150 |
Why?
|
| Cattle | 1 | 2020 | 394 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 454 | 0.140 |
Why?
|
| Esophageal Neoplasms | 1 | 2021 | 344 | 0.140 |
Why?
|
| Cell Proliferation | 1 | 2024 | 1735 | 0.140 |
Why?
|
| Microvessels | 1 | 2018 | 68 | 0.140 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 555 | 0.140 |
Why?
|
| Gene Expression Profiling | 2 | 2023 | 1517 | 0.130 |
Why?
|
| Computer Simulation | 3 | 2015 | 1120 | 0.130 |
Why?
|
| Genomics | 2 | 2023 | 848 | 0.130 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1166 | 0.130 |
Why?
|
| Adenocarcinoma | 4 | 2021 | 1173 | 0.130 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 214 | 0.130 |
Why?
|
| Subtraction Technique | 3 | 2006 | 125 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 1389 | 0.130 |
Why?
|
| Clinical Competence | 3 | 2009 | 821 | 0.130 |
Why?
|
| Information Storage and Retrieval | 3 | 2013 | 126 | 0.120 |
Why?
|
| Diet | 1 | 2020 | 461 | 0.120 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 2804 | 0.120 |
Why?
|
| False Negative Reactions | 2 | 2013 | 59 | 0.120 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2018 | 122 | 0.120 |
Why?
|
| Fourier Analysis | 1 | 2016 | 122 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 1339 | 0.120 |
Why?
|
| Early Detection of Cancer | 2 | 2018 | 504 | 0.110 |
Why?
|
| Neoplasms | 2 | 2022 | 3170 | 0.110 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 2756 | 0.110 |
Why?
|
| Adipose Tissue | 2 | 2008 | 271 | 0.110 |
Why?
|
| Area Under Curve | 5 | 2018 | 335 | 0.110 |
Why?
|
| Radiography | 3 | 2012 | 790 | 0.110 |
Why?
|
| Metabolic Clearance Rate | 1 | 2015 | 117 | 0.110 |
Why?
|
| Male | 12 | 2025 | 44582 | 0.110 |
Why?
|
| Autopsy | 2 | 2025 | 126 | 0.100 |
Why?
|
| Support Vector Machine | 1 | 2013 | 25 | 0.100 |
Why?
|
| Signal-To-Noise Ratio | 3 | 2019 | 113 | 0.100 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2013 | 34 | 0.100 |
Why?
|
| Cadaver | 2 | 2024 | 199 | 0.100 |
Why?
|
| Inflammation | 3 | 2024 | 1050 | 0.100 |
Why?
|
| Radiology Information Systems | 1 | 2013 | 78 | 0.100 |
Why?
|
| Medical Records | 1 | 2013 | 122 | 0.100 |
Why?
|
| Formaldehyde | 2 | 2023 | 51 | 0.100 |
Why?
|
| Models, Theoretical | 3 | 2018 | 494 | 0.090 |
Why?
|
| Phenotype | 2 | 2019 | 2545 | 0.090 |
Why?
|
| Breast Diseases | 2 | 2011 | 99 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 1715 | 0.090 |
Why?
|
| Echo-Planar Imaging | 2 | 2017 | 51 | 0.090 |
Why?
|
| Heart Failure | 1 | 2022 | 1388 | 0.090 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 100 | 0.090 |
Why?
|
| Postoperative Period | 1 | 2012 | 316 | 0.090 |
Why?
|
| Lymph Node Excision | 2 | 2013 | 233 | 0.090 |
Why?
|
| Illinois | 1 | 2013 | 520 | 0.080 |
Why?
|
| Prevalence | 2 | 2013 | 1322 | 0.080 |
Why?
|
| Precision Medicine | 1 | 2015 | 456 | 0.080 |
Why?
|
| Peptides | 2 | 2024 | 654 | 0.080 |
Why?
|
| Models, Biological | 2 | 2015 | 1769 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2018 | 2444 | 0.080 |
Why?
|
| False Positive Reactions | 3 | 2005 | 213 | 0.080 |
Why?
|
| Computer Terminals | 1 | 2009 | 7 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 1449 | 0.070 |
Why?
|
| Adolescent | 2 | 2019 | 9612 | 0.070 |
Why?
|
| Carcinoma, Ductal | 1 | 2008 | 18 | 0.070 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2008 | 36 | 0.070 |
Why?
|
| Cluster Analysis | 2 | 2026 | 392 | 0.070 |
Why?
|
| Carcinoma, Lobular | 1 | 2008 | 84 | 0.070 |
Why?
|
| Feasibility Studies | 3 | 2017 | 758 | 0.070 |
Why?
|
| Artifacts | 2 | 2018 | 243 | 0.060 |
Why?
|
| Animals | 5 | 2025 | 28047 | 0.060 |
Why?
|
| Ribs | 1 | 2006 | 49 | 0.060 |
Why?
|
| Benzamidines | 1 | 2025 | 3 | 0.060 |
Why?
|
| Guanidines | 1 | 2025 | 30 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2025 | 71 | 0.060 |
Why?
|
| Mice | 3 | 2024 | 12239 | 0.060 |
Why?
|
| Radiology | 2 | 2008 | 201 | 0.050 |
Why?
|
| Risk Factors | 2 | 2014 | 5914 | 0.050 |
Why?
|
| Arteries | 1 | 2025 | 171 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2026 | 2543 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2023 | 9110 | 0.050 |
Why?
|
| Swine | 1 | 2025 | 587 | 0.050 |
Why?
|
| Heart Atria | 1 | 2025 | 248 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2024 | 296 | 0.050 |
Why?
|
| Radiology, Interventional | 1 | 2004 | 62 | 0.050 |
Why?
|
| Viral Load | 1 | 2024 | 154 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2004 | 1932 | 0.050 |
Why?
|
| Paraffin Embedding | 1 | 2023 | 77 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2024 | 285 | 0.050 |
Why?
|
| Congo Red | 1 | 2022 | 5 | 0.050 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2023 | 44 | 0.050 |
Why?
|
| Intracranial Aneurysm | 1 | 2004 | 205 | 0.050 |
Why?
|
| Trypsin | 1 | 2022 | 90 | 0.050 |
Why?
|
| Quality Control | 2 | 2018 | 123 | 0.050 |
Why?
|
| Serum Amyloid A Protein | 1 | 2022 | 25 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2023 | 306 | 0.050 |
Why?
|
| Antigens, Surface | 1 | 2022 | 97 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2022 | 31 | 0.050 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2022 | 82 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2022 | 23 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2024 | 1102 | 0.050 |
Why?
|
| Surface-Active Agents | 1 | 2022 | 57 | 0.040 |
Why?
|
| Hormones | 1 | 2022 | 136 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2004 | 269 | 0.040 |
Why?
|
| Epitopes | 1 | 2022 | 249 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2023 | 257 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2022 | 490 | 0.040 |
Why?
|
| Antigens | 1 | 2022 | 223 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2022 | 148 | 0.040 |
Why?
|
| Esophagogastric Junction | 1 | 2021 | 35 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2023 | 200 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 465 | 0.040 |
Why?
|
| Fibrosis | 1 | 2022 | 230 | 0.040 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2020 | 25 | 0.040 |
Why?
|
| Antibodies | 1 | 2022 | 347 | 0.040 |
Why?
|
| Titanium | 1 | 2020 | 27 | 0.040 |
Why?
|
| Hepatitis B virus | 1 | 2020 | 47 | 0.040 |
Why?
|
| Aldehyde Dehydrogenase, Mitochondrial | 1 | 2020 | 2 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2022 | 712 | 0.040 |
Why?
|
| Catalysis | 1 | 2020 | 216 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 2466 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2022 | 454 | 0.040 |
Why?
|
| Animal Nutritional Physiological Phenomena | 1 | 2020 | 6 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2015 | 917 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2022 | 1171 | 0.040 |
Why?
|
| Machine Learning | 1 | 2023 | 345 | 0.040 |
Why?
|
| Saliva | 1 | 2020 | 124 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2020 | 234 | 0.040 |
Why?
|
| Ultraviolet Rays | 1 | 2020 | 192 | 0.040 |
Why?
|
| Germ Cells | 1 | 2020 | 130 | 0.040 |
Why?
|
| Myocytes, Cardiac | 1 | 2022 | 313 | 0.040 |
Why?
|
| Smoking | 1 | 2003 | 648 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2022 | 752 | 0.040 |
Why?
|
| Life Style | 1 | 2020 | 183 | 0.040 |
Why?
|
| Myocardium | 1 | 2022 | 570 | 0.040 |
Why?
|
| Gadolinium | 1 | 2019 | 96 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 188 | 0.040 |
Why?
|
| Forecasting | 1 | 2020 | 295 | 0.040 |
Why?
|
| Electric Conductivity | 1 | 2018 | 142 | 0.040 |
Why?
|
| Radiation Dosage | 3 | 2004 | 229 | 0.040 |
Why?
|
| RNA | 1 | 2022 | 574 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 660 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2020 | 502 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 2493 | 0.030 |
Why?
|
| Aging | 1 | 2022 | 727 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2022 | 2122 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 225 | 0.030 |
Why?
|
| Time | 1 | 2016 | 80 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2020 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1865 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1913 | 0.030 |
Why?
|
| Entropy | 1 | 2015 | 42 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 3143 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 3058 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 302 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1103 | 0.020 |
Why?
|
| Diagnostic Errors | 2 | 2005 | 157 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2013 | 107 | 0.020 |
Why?
|
| Software | 1 | 2017 | 671 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2014 | 196 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 413 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 1913 | 0.020 |
Why?
|
| Fats | 1 | 2011 | 12 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 572 | 0.020 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2014 | 190 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 884 | 0.020 |
Why?
|
| Injections | 1 | 2010 | 124 | 0.020 |
Why?
|
| Biological Transport | 1 | 2010 | 399 | 0.020 |
Why?
|
| Liquid Crystals | 1 | 2009 | 13 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 219 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 4266 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2004 | 147 | 0.010 |
Why?
|
| Carcinoma, Small Cell | 1 | 2004 | 115 | 0.010 |
Why?
|
| Time Factors | 1 | 2008 | 5406 | 0.010 |
Why?
|
| Incidence | 1 | 2003 | 1702 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 1077 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 3837 | 0.010 |
Why?
|